Chemed (NYSE:CHE) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share guidance of $10.60-10.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.01.

A number of research analysts recently issued reports on the stock. ValuEngine downgraded shares of Chemed from a buy rating to a hold rating in a research note on Friday, December 1st. Zacks Investment Research upgraded shares of Chemed from a hold rating to a buy rating and set a $251.00 price target for the company in a research note on Thursday, November 2nd. TheStreet upgraded shares of Chemed from a c+ rating to an a- rating in a research note on Friday, October 27th. Royal Bank of Canada lifted their price target on shares of Chemed to $232.00 and gave the stock a sector perform rating in a research note on Tuesday, October 31st. Finally, Oppenheimer lifted their price target on shares of Chemed from $220.00 to $225.00 and gave the stock an outperform rating in a research note on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $236.00.

Chemed (NYSE:CHE) traded up $4.35 during mid-day trading on Wednesday, reaching $253.73. 140,231 shares of the company’s stock were exchanged, compared to its average volume of 97,507. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. Chemed has a 12 month low of $170.54 and a 12 month high of $275.83. The firm has a market capitalization of $4,033.49, a PE ratio of 56.38 and a beta of 1.13.

In other Chemed news, VP Michael D. Witzeman sold 1,579 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $235.00, for a total transaction of $371,065.00. Following the sale, the vice president now owns 4,334 shares of the company’s stock, valued at $1,018,490. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Patrick Williams sold 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the sale, the insider now directly owns 74,857 shares in the company, valued at approximately $18,061,496.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,529 shares of company stock worth $3,741,746. 4.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/chemed-che-updates-fy18-earnings-guidance.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.